-
CanSino Biologics Receives Halal Certificate for COVID-19 Vaccine in Indonesia
•
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received a halal certificate from Indonesia’s LPPOM MUI for its recombinant novel coronavirus vaccine, which uses an adenovirus type 5 vector. This certification is a significant step for the company as it seeks to expand its vaccine’s reach…
-
Innovent Biologics’ Tafolecimab Receives NMPA Approval for Hypercholesterolemia Treatment
•
China-based Innovent Biologics Inc. (HKG: 1801) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its tafolecimab (IBI306), a recombinant fully human anti-PCSK-9 monoclonal antibody (mAb). The approved indication is for primary hypercholesterolemia, including heterozygous familial and non-familial hypercholesterolemia, as well as mixed…
-
European Commission Approves AbbVie’s Aquipta for Migraine Prevention in Adults
•
The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its drug Aquipta (atogepant), marking a significant milestone in the prevention of migraine in adults with four or more migraine days per month. Aquipta becomes the first once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist to receive…
-
BMS Announces Positive Phase I/II Results for Repotrectinib in ROS1-Positive NSCLC
•
Bristol-Myers Squibb (BMS, NYSE: BMY) has released new data from a Phase I/II trial featuring the ROS1/TRK blocker repotrectinib, which is being investigated for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The company celebrated the results, highlighting that the next-generation tyrosine kinase inhibitor (TKI)…
-
Immunofoco’s IMC008 Earns Orphan Drug Designation for Gastric Cancer from FDA
•
Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its next-generation autologous CAR-T therapy, IMC008, which is being developed to treat gastric cancer. IMC008: A Next-Generation CAR-T Therapy Utilizing SNR TechnologyIMC008 is grounded in Immunofoco’s…
-
Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer
•
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has announced an update on an ongoing Phase III oncology study involving a combination therapy that includes the HER2 inhibitor Tukysa (tucatinib), one of Seagen’s four marketed drugs that attracted Pfizer’s interest. The trial successfully met…
-
Medtronic’s Kanghui Partners with Huashan Hospital to Create Neuroscience Innovation Platform
•
US major Medtronic, Inc.’s (NYSE: MDT) unit, Kanghui, has entered into a partnership with Huashan Hospital, affiliated with Fudan University in Shanghai, to establish the “Neuroscience Industry Research Medicine Integration Innovation Platform.” This collaboration aims to advance the field of neuroscience, particularly in the areas of cerebrovascular diseases, brain occupying…
-
JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report
•
JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023 interim financial report, showing a 34% year-on-year (YOY) increase in total revenues to RMB 27.11 billion (USD 3.72 billion). Non-IFRS net profits surged by 101.2% to RMB 2.44 billion (USD 334.7 million), indicating strong financial…
-
Eisai’s Shanghai Unit Faces RMB 900,000 Penalty for Violating Drug Administration Law
•
Eisai Co., Ltd’s (TYO: 4523) Shanghai unit has been hit with an administrative penalty of RMB 900,000 (USD 124,000) by the Shanghai municipal market regulation administration bureau for violating Article 88 of the Drug Administration Law, as reported by “thepaper,” a local media outlet. Details of the Violation and Penalties…
-
Inmagene Biopharmaceuticals Initiates Global Study for IMG-007 in Atopic Dermatitis
•
China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study assessing the safety, pharmacokinetics, and efficacy of its pipeline candidate IMG-007. The molecule is being evaluated as a treatment for moderate-to-severe atopic dermatitis (AD), a condition that affects a significant patient population worldwide. IMG-007: An…
-
Sinovac Biotech Reports H1 2023 Financials with Significant Sales Decline from COVID-19 Boom
•
Sinovac Biotech Ltd (NASDAQ: SVA) has published its financial results for the first half of 2023, revealing a significant drop in sales from the COVID-19 surge experienced in the same period last year. Sales have fallen to USD 140.4 million, down from USD 1.2 billion in the first six months…
-
Gracell Biotechnologies Reports Q2 2023 Financials, Highlights GC012F in Melanoma Treatment
•
Suzhou-based biotech company Gracell Biotechnologies Inc., (NASDAQ: GRCL) has reported its financial results for the second quarter of 2023. The report highlights the company’s core product, GC012F, which has shown excellent data in multiple melanoma (MM) studies, as a key focus of their strategy moving forward. Clinical Trials and Development…
-
Legend Biotech Corporation Reports Q2 and H1 2023 Financials with Increased Revenues and R&D Spending
•
Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the second quarter and the first half of 2023. For the three months ended June 30, 2023, the company reported license revenue of USD 15.1 million, attributed to the achievement of a milestone during the quarter. Collaboration revenue reached…
-
Sanofi Misses Out on Acquiring Reata Pharmaceuticals to Biogen in USD 7.3 Billion Deal
•
Media outlet Bloomberg reported today that France-based Sanofi (NASDAQ: SNY) lost a bidding war to acquire neurological disease specialist Reata Pharmaceuticals (NASDAQ: RETA) last month. The company was ultimately purchased by US compatriot Biogen (NASDAQ: BIIB) for a substantial USD 7.3 billion. According to unnamed insiders cited by the source,…
-
Sandoz Achieves Primary Endpoint in Phase III Trial for Biosimilar Aflibercept
•
Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz (SWX: SDZ) has announced that a Phase III confirmatory trial for its biosimilar version of Bayer’s (ETR: BAYN) Eylea/Wetlia (aflibercept) has successfully reached its primary efficacy endpoint in neovascular (wet) age-related macular degeneration (nAMD). The study demonstrated that Sandoz’s biosimilar product showed no clinically…
-
Gilead Sciences Enters Collaboration with Tentarix Biotherapeutics for Polyspecific Antibodies
•
Gilead Sciences (NASDAQ: GILD) has announced the initiation of three collaboration programs with US-based Tentarix Biotherapeutics, focusing on the discovery and development of conditional polyspecific antibodies for oncology and inflammatory diseases. The collaboration underscores Gilead’s commitment to advancing innovative treatments in these therapeutic areas. Financial Terms and Acquisition RightsUnder the…
-
Amoy Diagnostics and AstraZeneca Expand Collaboration on Companion Diagnostic Development
•
China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced a new cooperation agreement with UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN), focusing on the development of a companion diagnostic (CDx). This collaboration builds upon a global strategic master collaboration agreement that was first signed at the end of 2021.…
-
Everest Medicines’ Partner Venatorx Pharmaceuticals Receives FDA Priority Review for Cefepime-Taniborbactam
•
China-based Everest Medicines (HKG: 1952) announced that its partner, Venatorx Pharmaceuticals, has received acceptance from the US Food and Drug Administration (FDA) for a New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic. The drug is intended for the potential treatment of adult patients with complicated urinary…
